Physician profile
Jennifer R Wright
NPI 1689844375
$3,593.82
in general payments reported to CMS, 2019-2025
36 companies · $732 in 2025
The $732 reported for 2025 was more than what 79% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $912 · 2022: $665 · 2023: $665 · 2024: $620 · 2025: $732.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,017.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,017.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $856.86 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $607.54 | 2021-2025 | |
| Glaxosmithkline, LLC. | $419.08 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $389.59 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $129.94 | 2022-2025 | |
| Exact Sciences Corporation | $128.95 | 2023-2024 | Cologuard Collection Kit |
| Supernus Pharmaceuticals, INC. | $96.10 | 2022-2025 | Qelbree, Qelbree |
| Amgen INC. | $71.82 | 2021-2025 | Otezla, Repatha |
| Takeda Pharmaceuticals U.S.A., INC. | $67.15 | 2021-2023 | Glassia |
| Xeris Pharmaceuticals, INC. | $66.50 | 2023-2025 | Gvoke Hypopen |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $64.66 | 2025 | Caplyta |
| Inogen, INC. | $63.64 | 2024-2025 | |
| Pfizer INC. | $63.20 | 2021-2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $60.36 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $55.41 | 2021-2024 | Xifaxan |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $50.97 | 2024-2025 | Injectafer |
| E.R. Squibb & Sons, L.L.C. | $37.00 | 2023 | Sotyktu, Eliquis |
| Tactile Systems Technology INC | $36.08 | 2023-2024 | Entre Plus, Flexitouch Plus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.89 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $25.67 | 2025 | Hetlioz, Fanapt |
| Kowa Pharmaceuticals America, INC. | $22.15 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $21.81 | 2021 | |
| Ardelyx, INC. | $21.50 | 2025 | Ibsrela |
| Boston Scientific Corporation | $21.29 | 2025 | General - Female Sui |
| Eisai INC. | $20.79 | 2024 | |
| Sanofi Pasteur INC. | $20.17 | 2025 | |
| Merck Sharp & Dohme LLC | $19.29 | 2021 | |
| Lundbeck LLC | $18.54 | 2023 | Rexulti |
| Axsome Therapeutics, INC. | $17.49 | 2025 | Auvelity |
| Novartis Pharmaceuticals Corporation | $16.68 | 2021 | |
| Astellas Pharma US INC | $14.82 | 2022 | |
| Mylan Specialty L.P. | $13.75 | 2024 | Yupelri |
| Currax Pharmaceuticals LLC | $13.43 | 2021 | |
| Dexcom, INC. | $12.07 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $11.91 | 2021 | |
| Phathom Pharmaceuticals, INC. | $9.72 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Wright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.